Neoadjuvant chemotherapy and targeted therapies: a promising strategy

Area of Science:

• Oncology
• Pharmacology
• Translational Research

Background:

• Neoadjuvant therapy is crucial for developing targeted breast cancer drugs.
• Availability of tumor tissue pre-treatment, surgery, and during treatment allows precise correlation of target identification, blockade, and response.
• Targeted agents have significantly improved neoadjuvant treatment outcomes.

Purpose of the Study:

• To highlight the significance of neoadjuvant therapy in accelerating targeted drug development for breast cancer.
• To emphasize the role of neoadjuvant research in bridging drug discovery and clinical application.
• To discuss the potential of neoadjuvant trials in streamlining the path to regulatory approval.

Main Methods:

• Utilizing pre-treatment tumor material for target identification and correlation with treatment response.
• Implementing targeted therapies, such as anti-HER2 agents, within neoadjuvant regimens.
• Leveraging ongoing research programs (e.g., NeoBIG, I-SPY 2) to validate neoadjuvant strategies.

Main Results:

• Anti-HER2 targeted therapies show increased pathological complete response rates in HER2-positive breast cancer.
• Identifying early surrogate markers is key to predicting treatment response in hormone receptor-positive breast cancer.
• Neoadjuvant research programs are poised to directly inform large phase III adjuvant trials.

Conclusions:

• Neoadjuvant therapy provides a powerful platform for targeted drug development in breast cancer.
• This approach can significantly shorten the timeline from drug discovery to regulatory approval.
• Ultimately, neoadjuvant strategies benefit patients by accelerating access to novel, effective treatments.